Summary
The D Sample, manufactured by Stanford, underwent independent testing to verify its composition and potency. The sample was submitted by Stanford and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the concentration of TB-500 (Thymosin Beta-4) at 9.08 mg, with a purity of 96.988%. Additionally, the sample contained 0.21 mg of semaglutide (unconfirmed).
The testing process began on 13 December 2023, with the sample received on 21 December 2023, and analysis completed on 3 January 2024. While the results confirm the presence and purity of TB-500, scrutiny of manufacturer-submitted samples remains essential to ensure consistency. Independent third-party testing is crucial to validate these findings comprehensively. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Stanford
- Product Name: D Sample
- Active Ingredient: TB-500 (Thymosin Beta-4)
- Batch Number: Not Provided
- Expiration Date: Not Provided
- Delivery Method: Viral Powder
Sample Acquisition and Testing
- Task Number: #37018
- Testing Ordered: 13 December 2023
- Sample Received: 21 December 2023
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Stanford (Manufacturer)
- Analysis Paid For By: Stanford (Manufacturer)
Testing Results
- Compound Detected: TB-500 (Thymosin Beta-4)
- Measured Concentration: 9.08 mg
- Purity: 96.988%
- Additional Finding: Semaglutide (0.21 mg, unconfirmed)
Verification Details
Verification URL: https://janoshik.com/tests/37018_YZW3S3QH2FM6
Evaluation of Manufacturer-Submitted Testing
This analysis confirms the presence of TB-500 in the tested sample with a measured purity of 96.988%. However, the detection of semaglutide (0.21 mg, unconfirmed) raises questions about the sample’s composition. Since Stanford submitted and funded the test, careful evaluation is needed to assess product consistency across different batches. While Janoshik Analytical is recognized for its transparency and rigorous testing protocols, these findings would benefit from independent validation through third-party testing across multiple samples.
Conclusion
The analysis confirms that the D Sample contains TB-500 (Thymosin Beta-4) at 9.08 mg with a purity of 96.988%. However, the presence of an additional unconfirmed semaglutide content (0.21 mg) underscores the importance of further third-party verification. This report is provided to support educational and harm reduction efforts, helping consumers make informed choices regarding peptide-based products.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
